TenderlineUK
Procurement Intelligence
Official OCDS
Find a Tender
active
Official procurement procedure

NHS Framework Agreement for the supply of Ranibizumab for the NHS in England

Pharmaceutical products
Various medicinal products
Yorkshire & Humber (UKE)
Published value
£120,000,000
Submission deadline 10 Feb 2023, 00:00 GMT
Lots published1
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: NHS England: "NHS Framework Agreement for the supply of Ranibizumab for the NHS in England". Published status: active. Published value: £120,000,000. 1 published lot. Recorded submission deadline: 10 Feb 2023, 00:00 GMT. See the official notice for participation instructions.
Contracting AuthorityNHS EnglandScope & CategoriesNot publishedSubmission Window
Closed
10 Feb 2023, 00:00 GMT
Submission GatewayDirect notice routeLegal Basis & RegimeStandard procurementEstimated Value (exc. VAT)£120,000,000
Bidder Intelligence · Authority Profile: NHS England
Market Analytics
View Authority Profile →
Derived from OCDS awards & bid statistics
Published history for NHS England. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Requires at least 5 comparable procedures
Competition Density
66.2Bids / Report
11.9% of reports have one bid
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate available
Payment Terms
Check noticePublished terms
Payment obligations depend on the applicable regime and contract. Consult the official documents.
Coverage: 515 active published awards; 512 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityNHS England
Procedure methodNot published
Procurement categoryNot published
Statusactive
Framework / DPSFramework
CompetitionNot published
Above thresholdNot published
Legal basisNot published
Tender period startsNot published
Clarification deadlineNot published
Electronic submissionNot published
Submission languagesNot published
Published9 Jan 2023, 15:19 GMT
Last source update9 Jan 2023, 15:19 GMT
Recurring procurementYes
ClassificationPharmaceutical products, Various medicinal products
Delivery area
Yorkshire & Humber (UKE)
OCIDocds-h6vhtk-0395f7
What is being bought
The Procurement relates to the supply of ranibizumab an Anti Veg-F medicine used in medical retinal vascular services for the NHS in England.<br/>Anti Veg-F medicines are currently used in the treatment of: <br/>a. neovascular (wet) age-related macular degeneration (AMD);<br/>b. visual impairment due to diabetic macular oedema (DME/DMO);<br/>c. visual impairment due to myopic choroidal neovascularisation (myopic CNV); and<br/>d. visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO).
What changed
From the official release history
  1. Published value updated to £120,000,000
    9 Jan 2023, 15:19 GMT
  2. Status changed to active
    9 Jan 2023, 15:19 GMT
  3. Official notice release published
    9 Jan 2023, 15:19 GMT
  4. Submission deadline changed to 10 Feb 2023, 00:00 GMT
    9 Jan 2023, 15:19 GMT
  5. Buyer information updated
    9 Jan 2023, 15:19 GMT
Lots and requirements (1)
Published by the contracting authority
  • Lot 1 · #1
    Individual lot title not published
    active
    Published value£120,000,000
    The Procurement relates to the supply of ranibizumab an Anti Veg-F medicine used in medical retinal vascular services for the NHS in England.<br/>Anti Veg-F medicines are currently used in the treatment of: <br/>a. neovascular (wet) age-related macular degeneration (AMD);<br/>b. visual impairment due to diabetic macular oedema (DME/DMO);<br/>c. visual impairment due to myopic choroidal neovascularisation (myopic CNV); and<br/>d. visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO).
    Contract periodNot published
    EligibilityNot published
    Options / renewalNot published
Timeline
  1. Procedure published
    9 Jan 2023, 15:19 GMT
  2. Submission deadline
    10 Feb 2023, 00:00 GMT
Commercial outcome and competition
AwardsNo award published
ContractsNo contract published
Bid statisticsNo aggregate bid statistics published
Buyer and organisations in this procedure

NHS England

Contracting authority GB-FTS-67205
View buyer profile
Documents (1)
Official links; attachments are not copied

  • economicSelectionCriteria

    tender
    economicSelectionCriteria
Related procedures (0)
No data
No related procedures published